Needham & Company LLC Reaffirms Hold Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Needham & Company LLC reissued their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note published on Tuesday morning, Benzinga reports.

Separately, StockNews.com raised shares of Lexicon Pharmaceuticals to a sell rating in a research report on Monday, April 15th.

Lexicon Pharmaceuticals Stock Up 2.6 %

Shares of NASDAQ LXRX opened at $1.58 on Tuesday. Lexicon Pharmaceuticals has a 12-month low of $0.92 and a 12-month high of $3.79. The stock has a market capitalization of $389.06 million, a price-to-earnings ratio of -1.97 and a beta of 1.27. The firm’s 50-day moving average price is $2.20 and its 200-day moving average price is $1.72. The company has a current ratio of 5.60, a quick ratio of 5.58 and a debt-to-equity ratio of 1.07.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. The business had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.68 million. On average, equities research analysts anticipate that Lexicon Pharmaceuticals will post -0.71 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. increased its position in Lexicon Pharmaceuticals by 22.0% during the 4th quarter. Victory Capital Management Inc. now owns 32,187 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 5,813 shares in the last quarter. Swiss National Bank increased its holdings in shares of Lexicon Pharmaceuticals by 4.4% during the third quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company’s stock valued at $264,000 after acquiring an additional 10,300 shares in the last quarter. Cantor Fitzgerald L. P. acquired a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at about $25,000. Pinnacle Associates Ltd. raised its position in shares of Lexicon Pharmaceuticals by 1.0% in the 1st quarter. Pinnacle Associates Ltd. now owns 1,747,830 shares of the biopharmaceutical company’s stock valued at $4,195,000 after purchasing an additional 17,009 shares during the last quarter. Finally, Principal Securities Inc. acquired a new stake in Lexicon Pharmaceuticals in the 4th quarter worth approximately $33,000. 74.70% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.